Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Friday’s Top Upgrades (and Downgrades): Angie’s List Inc (ANGI) and More

Page 1 of 2

This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on. Today, our headlines include higher price targets for both Zebra Technologies Corp. (NASDAQ:ZBRA) and Stanley Black & Decker, Inc. (NYSE:SWK). Unfortunately, it’s not all good news. So let’s start with a quick rundown of why…

Angie's List Inc (NASDAQ:ANGI)Angie’s off the buy list
Angie’s List Inc
(NASDAQ:ANGI) shares surged 24% in Thursday trading, responding well to the online contractor-evaluator’s confirmation that it beat earnings estimates in the fourth-quarter with a $0.04-per-share profit — when a $0.02-per-share loss had been expected. Angie’s promise of $51 million or more in fiscal 2013 revenues — also ahead of estimates — didn’t hurt, either.

Nevertheless, the quick turnaround in sentiment over Angie’s List has one analyst thinking now is a great time to get while the getting’s good. As related, Barrington worries that: “given this dramatic price increase … the stock could trade sideways or down in the near term due to profit taking.”

Worse, Angie’s still expected to lose money next year. Barrington estimates the company could report as much as a $0.15-per-share loss in the current first quarter “due to seasonality.” Barrington is therefore downgrading to “market perform,” reasoning that investors should take profits now, then wait on the sidelines for another buying opportunity.

Well, they’re half right. Angie may have made a small profit in the fourth quarter, but the fact remains that the company remains a deeply unprofitable operation year-round. Full-year net losses at Angie are still pushing $53 million. The rate of negative free cash flow, meanwhile, topped $43 million, and is still rising. Considering the market is currently valuing this cash-burning machine at nearly $1 billion, I’d say that if you were lucky enough to make a profit on Angie yesterday, the better advice is to take profits now… and don’t look back.

Green Zebra?
A second company reporting positive earnings news this week was Zebra Technologies, a maker of RFID “smart-label” printers that reported healthy $0.68-per-share profits Tuesday, when the market was looking for only $0.67. After crunching the numbers, Imperial Capital announced today that it’s upping its price target on Zebra to $45… but still not recommending the stock.

And once again — they’re half right about that.

Priced at nearly 19 times earnings, but projected to grow these earnings at barely 8% annually over the next five years, Zebra looks horribly overvalued at first glance. Read between Zebra’s lines, of course, and you’ll find the company generates lots of cash ($161 million last year)as well as holding lots of the green stuff (about $390 million) in the bank.

That still only works out to an enterprise value-to-free cash flow ratio of 12, however, and given the slow growth rate and lack of any dividend payment, it’s still not quite enough to justify buying Zebra. In fact, considering that the midpoint of Zebra’s guidance this week actually fell a bit short of expectations, I wouldn’t be at all surprised to see the stock fall back a bit.

Stanley could power higher
And finally, we close with a real rarity during earnings season: a stock that’s getting a price target hike despite not having any earnings news whatsoever to report.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!